A new study, presented at the American Society of Radiation Oncology Annual Meeting, shows that patients who received radiation therapy before chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma were less likely to have severe treatment-related toxicities; none of the patients who received induction radiation therapy less than 30 days before CAR T-cell infusion experienced high-grade cytokine release syndrome or neurotoxicity, two of the common treatment-related toxicities associated with CAR T-cell therapy